Form 4 for GILD Gilead Sciences
Accepted 2023-03-14 00:00:00 ET · period of report 2023-03-10 · accession 0001127602-23-010012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-14 | 2023-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | +30.3K | 379.0K | +9% | — |
| D | 2023-03-14 | 2023-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | F - Tax | $79.50 | -14.0K | 375.8K | -4% | -$1.11M |
| DM | 2023-03-14 | 2023-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | A - Grant | $0.00 | +262.3K | 215.1K | New | $0 |
| DM | 2023-03-14 | 2023-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | -30.3K | 85.8K | -26% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-10 | M | A | 10,800 | — | 389,783 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2023-03-10 | M | A | 19,488 | — | 378,983 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 3 | Common | Common Stock | 2023-03-10 | F | D | 14,017 | $79.50 | 375,766 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2023-03-10 | A | A | 47,170 | — | 132,933 | D | — · — to — | 47,170 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2023-03-10 | A | A | 215,095 | $0.00 | 215,095 | D | $79.50 · — to 2033-03-10 | 215,095 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Restricted Stock Unit | 2023-03-10 | M | D | 19,488 | — | 96,563 | D | — · — to — | 19,488 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2023-03-10 | M | D | 10,800 | — | 85,763 | D | — · — to — | 10,800 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |